Save ComparisonClear all | ![]() CymaBay Therapeutics CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. | ![]() Collegium Pharmaceutical Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain. | ![]() Esperion Therapeutics Esperion Therapeutics discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. | ![]() Cara Therapeutics Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation. | ![]() RXi Pharmaceuticals RXi Pharmaceuticals develops therapeutics based on ribonucleic acid interference. |
Founding Date | Founding Date 1991 | Founding Date 2002 | Founding Date 2008 | Founding Date 2004 | Founding Date 2011 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Newark, US HQ | Locations Canton, US HQ | Locations Ann Arbor, US HQ | Locations Stamford, US HQ | Locations Marlborough, US HQ |
Employees | Employees 21 | Employees 234 | Employees 44 | Employees 34 | Employees 15 |
Valuation ($) | Valuation ($) 453.4 m | Valuation ($) 754.2 m | Valuation ($) 1.8 b | Valuation ($) 394.1 m | Valuation ($) 6.3 m |
Twitter followers | Twitter followers N/A | Twitter followers N/A | Twitter followers 895 | Twitter followers N/A | Twitter followers 216 |
Financial | |||||
Net income | Net income ($27.6m) (FY, 2017) | Net income ($74.9m) (FY, 2017) | Net income ($75m) (FY, 2016) | Net income N/A | Net income ($12.5m) (FY, 2017) |